By Devika Patel
Knoxville, Tenn., March 16 - OccuLogix, Inc. gave further details about a $5 million registered direct offering of stock in a prospectus supplement filed Tuesday with the Securities and Exchange Commission. The deal priced Monday.
The company will sell 1,552,795 common shares at $3.22 apiece. The investors also will receive warrants for 621,118 shares, which are each exercisable at $4.00 for 18 months.
Rodman & Renshaw, LLC is the agent.
Settlement is expected March 18.
Proceeds will be used for working capital and general corporate purposes.
Boston-based OccuLogix develops ophthalmic devices to treat age-related eye diseases.
| Issuer: | OccuLogix, Inc.
|
| Issue: | Common shares
|
| Amount: | $5 million
|
| Shares: | 1,552,795
|
| Price: | $3.22
|
| Warrants: | For 621,118 shares
|
| Warrant expiration: | 18 months
|
| Warrant strike price: | $4.00
|
| Agent: | Rodman & Renshaw, LLC
|
| Pricing date: | March 15
|
| Settlement date: | March 18
|
| Stock symbol: | Nasdaq: TEAR
|
| Stock price: | $3.79 at close March 12
|
| Market capitalization: | $30.2 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
